Phase 3 Clinical Trials With Primary Completion Dates in March 2021
This is a list of Phase 3 trials with primary completion dates in March 2021 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| AGLE | Aeglea BioTherapeutics, Inc. | 2021-03-01 | Phase 3 | NCT03921541 | Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency |
| ARQT | Arcutis Biotherapeutics, Inc. | 2021-03-01 | Phase 3 | NCT04286607 | Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis |
| HGEN | Humanigen, Inc. | 2021-03-01 | Phase 3 | NCT04351152 | Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19 |
| MMSI | Merit Medical Systems, Inc. | 2021-03-01 | Phase 3 | NCT01387932 | HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer |
| NEPH | Nephros, Inc. | 2021-03-01 | Phase 3 | NCT03534284 | Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis |
| RIGL | Rigel Pharmaceuticals, Inc. | 2021-03-01 | Phase 3 | NCT03764618 | A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA |
| SYNH | Syneos Health, Inc. | 2021-03-01 | Phase 3 | NCT04541004 | Adolescent Mite Allergy Safety Evaluation |